# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-22 (automated, unattended)
**Scope:** Review of latest script outputs in `Analysis/Results/` + 7-day web scan
**Prior report:** `monitor_report_2026-07-16.md`

---

## Headline (read this first)

**The trial and PubMed pipelines have not refreshed since 2026-07-17 — they are 5 days stale.** Everything below the gap analysis is built on a July 17 snapshot. The gap analysis (07-21) and agent_state backup (07-21) are current, so the hub is running, but `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` appear to have stopped producing daily snapshots after 07-17. **Re-run both before trusting any "current trial status" claim.** [Certain — file mtimes confirm it]

**Most significant external event:** Retatrutide (a tracked therapy) reported its **first Phase 3 results** at ADA 2026 — triple-hormone GIP/GLP-1/glucagon agonist, ~2% A1c reduction in T2D (TRANSCEND-T2D-1) and ~70 lbs mean weight loss in obesity (TRIUMPH-1). This is a landmark readout and our snapshot predates full incorporation. [Likely — press/secondary sources, not yet cross-checked against the primary NEJM/ADA publication]

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 5 days | **Stale** |
| `pubmed_recent_latest.json` | 2026-07-17 | 5 days | **Stale** |
| `hub_monitor_report.md` | 2026-07-17 | 5 days | **Stale** |
| `literature_gap_data.json` | 2026-07-18 | 4 days | Aging |
| `literature_gap_report.md` | 2026-07-21 | 1 day | Current |
| `agent_state.json` | 2026-07-21 | 1 day | Current |
| Latest CT snapshot | `clinical_trials_snapshot_2026-07-17.json` | 5 days | No snapshots 07-18→07-22 |
| Latest PubMed snapshot | `pubmed_recent_snapshot_2026-07-17.json` | 5 days | No snapshots 07-18→07-22 |

The 07-17 `hub_monitor_report.md` itself flagged **827 result files older than 14 days**. That count reflects the large archive of dated snapshots/backups, not a pipeline fault — but the absence of any 07-18 through 07-22 trial/PubMed snapshot is a real gap.

---

## Clinical Trial Changes

Latest snapshot: **858 total trials** (152 T1D cure/cell therapy, 76 T1D immunotherapy/prevention, 147 T2D novel, 236 devices, 321 recently completed w/ results).

**Phase 3 RECRUITING: 52 trials.** Highest-priority active programs:

- **VX-880 (Vertex) — NCT06832410 & NCT04786262**, Phase 3, RECRUITING. Zimislecel/VX-880 islet-cell therapy for T1D. *Note: tracked as `zimislecel` returns 0 hits but `VX-880` returns 2 — the therapy tracker is keyed on the generic name while trials use the code. Alias mapping needed.* [Certain]
- **Baricitinib (Eli Lilly) — NCT07222332 & NCT07222137**, Phase 3, beta-cell preservation and Stage-3 delay in T1D.
- **Teplizumab (Sanofi) — NCT07088068**, Phase 3 vs placebo (see Breaking News — Tzield just gained a pediatric FDA indication).
- **CagriSema (Novo Nordisk) — NCT07564414**, Phase 3 dose-ranging.
- **Insulin icodec (Novo Nordisk) — NCT07076199**, Phase 3 weekly insulin.
- **Elecoglipron (AstraZeneca) — NCT07662135 / NCT07662044 / NCT07662109 / NCT07662213**, cluster of new Phase 3 starts (posted 2026-06-23).

**Change vs. the 2026-03-15 baseline snapshot** (4-month delta): **+174 new trials, −62 removed, 55 status changes.** Of the new trials, 39 are Phase 3 or key-sponsor. Notable new Phase 3 registrations:

- Orforglipron (Eli Lilly) — several new Phase 3 starts (NCT07668336, NCT07613307).
- Enicepatide (Roche) — NCT07670416, NCT07351058.
- UBT251, Bofanglutide, GZR33, HDM1002/1005 — a wave of new incretin/oral candidates from Asian pharma.

**Notable status changes since 03-15:**

- NCT01897688 (Northwestern, Phase 3): ACTIVE → **COMPLETED**.
- NCT06972472 & NCT06993792 (Eli Lilly, Phase 3): RECRUITING → ACTIVE_NOT_RECRUITING (enrollment closed — results pipeline).
- NCT07271251 (Novo Nordisk, Phase 3): RECRUITING → ACTIVE_NOT_RECRUITING.

**Recently posted results:** 109 trials carry a 2026 `results_posted` date in the current snapshot; 77 are new since the 03-15 baseline. Highest-signal: **Orforglipron (Eli Lilly) NCT05971940 (2026-04-22) and NCT06010004 long-term safety (2026-06-30)** — worth pulling for the drug-repurposing / GLP-1 evidence network.

---

## PubMed Highlights

Latest pull: **158 unique papers**, 30-day lookback, 16 domains.

**Cross-domain papers (12 — highest value).** Top picks aligned to our Tier 1 areas:

- **[42459945]** "A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes" — spans **AI/ML + Closed Loop AP + Health Equity** (3 domains). Directly on the Tier 1 AI/ML-prediction and epidemiology/equity intersection. [Certain — in file]
- **[42419792]** "Comparative effects of drugs for adults with overweight or obesity: systematic review" — links **orforglipron + retatrutide + CagriSema** (three tracked therapies in one paper). High value for trial-intelligence cross-mapping.
- **[42458730]** and **[42459212]** — both **Microbiome + Multi-Omics** (Tier 1 multi-omics integration).
- **[42437645]** "Variant-specific pharmacophoric shifts in GLP-1 receptor" — **GLP-1 Pharmacogenomics + orforglipron**.

**Key-therapy publication activity (30-day):** dapagliflozin 52 hits / orforglipron 10 / CagriSema 6 / retatrutide 4 / teplizumab 4 / icodec 3 / baricitinib 2 / **zimislecel 0**. The zero for zimislecel is a tracker alias problem, not an absence of activity (VX-880 is in active Phase 3).

**Volume by domain (paper_count capped at 10/query; total_count shows raw activity):** AI/ML (260 raw), Microbiome (186), GLP-1 New (167), Biomarker (166) run hottest. LADA (12) and Drug Repurposing (8) remain thin — consistent with the gap analysis.

**Day-over-day (07-16→07-17, from hub_monitor):** 28 new papers, 27 dropped, 3 cross-domain. Normal churn.

---

## Gap Analysis Summary (current — 2026-07-21)

435 domain pairs analyzed across 30 domains. Top under-researched intersections (Gap Score, BRONZE confidence — single analytic source, needs expert confirmation):

| Rank | Intersection | Gap | Joint Pubs |
|------|-------------|-----|-----------|
| 1 | Treg/CAR-T × Neuropathy | 100 | 0 |
| 2 | Beta Cell Regen × Health Equity | 100 | 0 |
| 3 | Treg/CAR-T × Health Equity | 100 | 0 |
| 4 | Glucokinase × Health Equity | 100 | 0 |
| 5 | Gene Therapy × LADA | 100 | 0 |

**Alignment with our Tier 1 contribution areas:** Four of the top five touch **Health Equity (Tier 1 #6, Epidemiological/Disparity analysis)** or **Literature Synthesis (Tier 1 #2)**. The "Beta Cell Regen × Health Equity" and "Gene Therapy × LADA" gaps are the most actionable for a computational synthesis contribution — both are real BRONZE gaps in domains where we have data access and no device/wet-lab dependency. Recommend promoting one to a SILVER validation task (query PubMed with combined MeSH + check Cochrane/PROSPERO for existing reviews) per the Doctrine's escalation path.

Caveat carried from the report: these are keyword-based, BRONZE-level, and several may be terminology artifacts rather than true gaps.

---

## Breaking News (7-day web scan)

- **Retatrutide Phase 3 readouts at ADA 2026** — TRIUMPH-1 (obesity, ~70 lb mean loss) and TRANSCEND-T2D-1 (T2D, ~2% A1c reduction from 7.9% baseline), plus signals on OSA and knee OA pain. First Phase 3 data for the triple-hormone class. Retatrutide is a tracked therapy; our 07-17 snapshot predates this. [Likely — secondary sources]
- **Tzield (teplizumab, Sanofi) — FDA pediatric indication granted 2026-06-12** to delay insulin decline in children 8–17 with recently diagnosed Stage 3 T1D, on the Phase 3 PROTECT trial (n=328). Directly relevant to tracked trial NCT07088068. [Likely]
- **Insulin efsitora alfa (Eli Lilly) — FDA decision expected July 2026**; no confirmed approval found as of this scan. Watch item. [Guessing — no primary confirmation of outcome]
- **Awiqli (insulin icodec, Novo Nordisk)** — first once-weekly basal insulin, FDA approved March 2026 (context for the icodec Phase 3 NCT07076199). [Likely]

Routine ADA-preview and pipeline-roundup coverage otherwise; nothing else meets the significance bar.

---

## Recommended Actions

1. **Refresh the stale pipelines first.** Run `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py` — no trial/PubMed snapshot exists for 07-18 through 07-22. Then re-run `python hub_monitor.py` to regenerate the change diff.
2. **Fix the therapy-tracker alias map.** Add `zimislecel ↔ VX-880` (and check other generic/code pairs) so the tracker stops reporting 0 activity for an active Phase 3 asset. [Certain this is a defect]
3. **Pull the retatrutide Phase 3 data** into the trial-intelligence and evidence network once the primary ADA/NEJM publication is available; flag TRANSCEND-T2D-1 and TRIUMPH-1. Cross-check the ~2% A1c and ~70 lb figures against the primary source before recording as anything above BRONZE.
4. **Update the tracker** (`Diabetes_Research_Tracker.xlsx`) with the AstraZeneca elecoglipron Phase 3 cluster (NCT07662135/044/109/213) and the Vertex VX-880 Phase 3 pair — all new or newly-flagged since the March baseline.
5. **Review cross-domain paper [42459945]** (AI/ML × Closed Loop × Health Equity) — sits on the intersection of two Tier 1 areas and a top-5 gap theme; candidate for a synthesis write-up.
6. **Promote one top-5 gap to SILVER.** "Beta Cell Regen × Health Equity" or "Gene Therapy × LADA": run combined-term PubMed + Cochrane/PROSPERO check to confirm the gap is real, not a keyword artifact.
7. **Confirm the efsitora alfa FDA outcome** on the next run — decision was due this month.

---

*Evidence levels per RESEARCH_DOCTRINE.md. New external claims are marked [Likely]/[Guessing] pending primary-source verification. This was a read-only review run — no hub files were modified.*
